Dr. Deitcher is an innovative business leader who has more than 25 years of life science product development experience including cellular therapeutics, biologics, small molecules, and diagnostics. He was President, CEO and Board Member at Talon Therapeutics, a specialty biopharmaceutical company focused on novel cancer drug delivery. At Talon, his team advanced its lead compound, Marqibo®, from IND to FDA accelerated approval to treat leukemia and positioned the company for sale to Spectrum Pharmaceuticals. He previously served as Vice President and Chief Medical Scientist at Nuvelo. He was formerly the Chief of Hematology and Director of Thrombosis and Vascular Medicine Research at The Cleveland Clinic and held leadership positions at The University of Tennessee Health Science Center and St. Jude Children’s Research Hospital.
He received his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University. He is a member of several corporate and university advisory boards and has authored 225 publications in medical and scientific journals.
Peter Kolchinsky is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, and serves as a Board Member for various public and privately held companies, including Dicerna Pharmaceuticals, Inc. and Wave Life Sciences Ltd. Peter also leads the firm's outreach and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policy makers, and industry. He authored "The Entrepreneur's Guide to a Biotech Startup" and served on the Board of Global Science and Technology for the National Academy of Sciences.
Peter holds a BS from Cornell University and a PhD in Virology from Harvard University.
Dr. Kung is a founding member of Vivo Capital, LLC, a healthcare and biotechnology venture capital management firm headquartered in Palo Alto, California and 35 year veteran of the biotechnology industry. Dr. Kung started his career in the biotechnology industry when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation, which was acquired by its parent company. In 1984 he co-founded Genelabs Technologies, Inc., where he served as Chairman and CEO until 1995.
Dr. Kung received his B.S. in chemistry from the National Tsing Hua University in Taiwan and his Ph.D. in molecular biology and M.B.A. from the University of California, Berkeley. Dr. Kung currently serves on the board of directors of a number of emerging healthcare and biotechnology companies.
Prior to joining WuXi Healthcare Ventures, Dr. Li focused his effort on healthcare and life science investment opportunities at Fidelity Biosciences, Fidelity Growth Partner Asia, and Baird Venture Partners. He also led drug discovery projects and technology licensing due diligence at Vertex Pharmaceuticals, an biotech company in Boston, MA. During his scientific career, Wei first-authored numerous scientific publications in journals including Science, Proceedings of the National Academy of Sciences, and Journal of Biological Chemistry.
Wei received a B.S., with distinction, in Chemical Physics from University of Science and Technology of China, a Ph.D. in Biochemistry and Mammalian Genetics from Harvard University, and an MBA from the Kellogg School of Management at Northwestern University, where he was elected Beta Gamma Sigma, with a concentration in Finance, Accounting and Marketing.
Anand joined Sofinnova in 2007 as a Principal. In 2014, he was promoted to General Partner. He focuses on working with entrepreneurs to build drug development companies that have the power to improve the lives of patients. Anand represents Sofinnova on the boards of Aclaris (ACRS), Amplyx, Merus (MRUS), and Spark Therapeutics (ONCE). Prior to joining Sofinnova, Anand worked at JP Morgan Partners in private equity and venture capital. Before joining the venture community, he was a consultant for McKinsey & Company's healthcare practice, advising large pharmaceutical and biotech companies on core strategic issues. Anand received his MD from Columbia University's College of Physicians and Surgeons. He was an Echols Scholar and conducted National Institute of Health sponsored research on the outcomes, mechanisms, and pre-clinical development of therapeutic agents for stroke.
He graduated Phi Beta Kappa from the University of Virginia with a BA in Political Theory through the Government Honors program. While in college, he spent three years as a firefighter for the Seminole Trail Fire Department.